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Abstract
In December 2019, a novel coronavirus, named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) or
(2019-nCoV) with unknown origin spread in Hubei province of China. The epidemic disease caused by SARS-CoV-2
called coronavirus disease-19 (COVID-19). The presence of COVID-19 was manifested by several symptoms, ranging
from asymptomatic/mild symptoms to severe illness and death. The viral infection expanded internationally and
WHO announced a Public Health Emergency of International Concern. To quickly diagnose and control such a
highly infectious disease, suspicious individuals were isolated and diagnostic/treatment procedures were developed
through patients’ epidemiological and clinical data. Early in the COVID-19 outbreak, WHO invited hundreds of
researchers from around the world to develop a rapid quality diagnosis, treatment and vaccines, but so far no
specific antiviral treatment or vaccine has been approved by the FDA. At present, COVID-19 is managed by
available antiviral drugs to improve the symptoms, and in severe cases, supportive care including oxygen and
mechanical ventilation is used for infected patients. However, due to the worldwide spread of the virus, COVID-19
has become a serious concern in the medical community. According to the current data of WHO, the number of
infected and dead cases has increased to 8,708,008 and 461,715, respectively (Dec 2019 –June 2020). Given the
high mortality rate and economic damage to various communities to date, great efforts must be made to produce
successful drugs and vaccines against 2019-nCoV infection. For this reason, first of all, the characteristics of the virus,
its pathogenicity, and its infectious pathways must be well known. Thus, the main purpose of this review is to
provide an overview of this epidemic disease based on the current evidence.
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Background
In December 2019, an outbreak of pneumonia with un-
known origin began in China’s Hubei Province, raising
global health concerns due to the ease of transmission.
To quickly diagnose and control the highly infectious
disease, suspected people were isolated and diagnostic/
therapeutic procedures were developed via patients’ epi-
demiological and clinical data. After numerous studies, a
novel severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) was identified as the cause of the disease,
and the disease was dubbed “coronavirus-19″ (COVID-
19) by Chinese Scientists [1, 2]. The presence of
COVID-19 is manifested by several symptoms, ranging
from asymptomatic/mild symptoms to severe illness and
death. Common symptoms include cough, fever, and
shortness of breath. Other reported symptoms are weak-
ness, malaise, respiratory distress, muscle pain, sore
throat, loss of taste and/or smell [3].
Clinical diagnosis of COVID-19 is based on clinical
manifestations, molecular diagnostics of the viral gen-
ome by RT-PCR, chest x-ray or CT scan, and serology
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blood tests. The most common laboratory abnormal-
ities in patients with positive RT-PCR are lymphope-
nia, leukopenia, thrombocytopenia, elevated CRP and
inflammatory markers, elevated cardiac biomarkers,
decreased albumin, and abnormal renal and liver
function [4, 5]. However, several parameters may
interfere with the results; the most important of
which is the window period (time from exposure to
the development of symptoms). As the body requires
time to respond to the antigenic viral attack, symp-
toms may appear 2 to 14 days after exposure to the
virus. The window-period of viral replication leads to
false-negative results and problems in preventing
COVID-19 expansion.
There have been two types of tests for COVID-19
during this pandemic: One type is PCR tests, as a
molecular diagnostic technique based on viral genetic
material that can diagnose an active COVID-19 infec-
tion. The early detection of COVID-19 via PCR de-
pends on the presence of a sufficient amount of viral
genome in the patient sample [6, 7] and the sensitiv-
ity of the RT-PCR assay. So, optimized or screening
methods that able to detect the 2019-nCoV even in
low viral titers are fairly necessary. The other type is
serological tests based on antibodies against viral pro-
teins. Serological tests identify people who have devel-
oped an adaptive immune response to the virus, as
part of an active/or prior infection. Three types of
antibodies including IgG, IgM, and IgA may be de-
tected in response to the virus, especially IgM which
is produced early after the infection [8]. It seems that
serological tests, along with PCR increase the sensitiv-
ity/accuracy of the diagnosis, but due to window-
period, immune tests do not help diagnose and screen
in early infection. After infection with 2019-nCoV, it
takes 2 weeks or more for antibodies to be detected
[9]. Thus, early IgM/IgG antibody tests cannot detect
active viral shedding in early infection, and if an indi-
vidual is infectious. In other words, due to the direct
identification of viral RNA, molecular tests are more
sensitive than immune and serological tests in the
diagnose of primary infection and can accelerate early
screening even during the incubation period of
COVID-19 (before symptom onset). So, immune tests
will be practical and necessary for the event of a sec-
ond recurrence of the virus in the society. Chinese re-
searchers have reported a variety of results related to
immune response, such as a broad range of antibodies
between people with mild symptoms of the virus,
while fewer antibodies among younger people, and no
trace of antibodies in some individuals [10]. Thus the
question arises as to whether a person with a positive
RT-PCR test and severe, mild, or asymptomatic infec-
tion may still be prone to a second infection.
Coronavirus Virology
A human coronavirus was isolated for the first time
from the nasal secretions of a male child with a common
cold in 1965 by Tyrell and Bynoe [11]. Because of their
morphological similarity with a solar corona under an
electron microscope (crown-like), the virus was termed
coronavirus. Such appearance is because of the spike [S]
glycoprotein radiating from the viral surface virus (Fig.
1). The S glycoprotein and the transmembrane glycopro-
tein [M] are two major envelope proteins. The S glyco-
protein is an antigen that binds to the receptor and is
responsible for cellular fusion. M glycoprotein has a role
in envelope formation and virion assembly [10, 12]. The
positive single-stranded RNA genome with about 26–32
Kbp, is the largest genomic RNA known among viruses
and contains 7–10 different open reading frames. It is
methylated in 5′ and has a poly-A tail in 3′. Genomic
RNA is associated with the capsid by the basic phospho-
protein [N] [13, 14].
The Coronaviruses have four subfamilies including
alpha, beta, gamma, and delta. The alpha and beta coro-
naviruses originate from mammals, while gamma and
delta coronaviruses have been identified in pigs and
birds. Beta-coronaviruses are also called bat-coronavirus.
Bioinformatics analysis shows that RNA sequence of
2019-nCoV is more than 90% similar to a bat-
coronavirus RaTG13. It has been reported that the beta-
coronaviruses cause severe disease while the alpha-
coronaviruses cause asymptomatic or mildly symp-
tomatic disease [15, 16]. 2019-nCoV is closely related
to the B lineage of the beta-coronaviruses, which are
known to cause severe disease and fatalities [17]. To
determine amino acid sequence and structure of
2019-nCoV proteins and subsequently to predict their
interactions to host cells, the complete virus genome
was sequenced and also was deposited in NCBI (Gen-
Bank: MN908947.3). Studies have revealed the outer
membrane spike glycoprotein as the prime viral adhe-
sion factor interacts with host cell targets such as
ACE2, Ezrin, CD26, cyclophilins, and other cell adhe-
sion factors [18, 19].
Comparison of the Coronaviruses
The recent COVID-19 outbreak may be comparable
with the outbreaks of the SARS-CoV (2002–2003) in
China and with the Middle East Respiratory Syndrome
Coronavirus (2012) in Saudi Arabia for their zoonotic
transmission and some similarities in clinical features
[20]. However, phylogenetic analysis (Fig. 2) of the
receptor-binding domain (RBD) of betacoronavirus line-
ages indicates that 2019-nCoV closely belongs to two
bat-derived SARS-like coronaviruses (bat-SL-CoVZC45
and bat- SL-CoVZXC21) with 88–89% similarity,
whereas its similarity to the SARS-CoV and MERS-CoV
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is 50 and 79%, respectively [22]. It is worth noting that
although there are significant genetic differences be-
tween these coronaviruses and the subgroup with 2019-
nCoV, cross-reactions in RT-PCR or antibody measure-
ments for SARS or other beta-coronaviruses my occur, if
the primers and antigenic epitopes are not carefully se-
lected [23, 24].
RBD located at the C-terminal domain of the spike
protein mostly attaches to angiotensin-converting en-
zyme 2 (ACE2) located in the host cell membrane.
Fig. 1 Typical structure of 2019-nCoV
Fig. 2 The phylogenetic illustration of the receptor-binding domain (RBD) in various betacoronaviruses a. The structure of RBD in SARS-CoV b,
2019-nCoV c, and MERS-CoV d [21]
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ACE2 is mainly distributed in the epithelial cells of the
lung and gastrointestinal tract. So, severe infection may
occur in tissues with high expression levels of ACE2 in-
cluding lung, intestine, kidney, and blood vessels [25].
Using the Swiss-Model program 33, the three-
dimensional structure of the 2019-nCoV-RBD (Protein
Data Bank ID: 2DD8), like the RBD in other beta-
coronaviruses, consists of a core and an external subdo-
main (Fig. 2b-d). Interestingly, the similarity among the
external subdomain of RBD in 2019-nCoV with that in
SARS-CoV suggests the 2019-nCoV also uses ACE2
binding to entre into the host cell [25]. Moreover, the
modeling studies have disclosed several RBD residues re-
sponsible for the binding of the 2019-nCoV to the ACE2
receptor, such as Asn439, Asn501, Gln493, Gly485, and
Phe486 that differ from those in the SARS-CoV-RBD [6,
26].
Pathogenesis of the 2019-nCoV
Acute 2019-nCoV infections are very similar to seasonal
flu with the most common symptoms of fever, headache,
shortness of breath, cough, muscle aches, and tiredness
[1, 27]. The severity of the disease in most infected
people is mild to moderate, and they can manage their
symptoms at home without the need for hospitalization.
While patients with serious symptoms such as difficulty
breathing, chest pain or pressure, and loss of speech or
movement need urgent medical attention. Other disor-
ders seen in acute conditions include hemoptysis, diar-
rhea, dyspnea, acute heart injuries, and ground-glass
opacities.
The lungs are the primary site of 2019-nCoV infection.
The chest CT of the infected patients usually shows bi-
lateral ground-glass opacity lesions in the posterior and
peripheral lungs that are reported as the characteristic of
2019-nCoV pneumonia [28]. Pathologic studies on bi-
opsy samples of lung, liver, and heart obtained from
death COVID-19 patients have revealed that the lung is
the main affected tissue with pathological changes in-
cluding hyperplasia of type II pneumocytes, damage to
the alveolar epithelial cells, the formation of the hyaline
membrane and diffuse alveolar damage [29]. Thrombotic
microangiopathy, significant accumulations of CD4+
mononuclear cells around small thrombotic vessels, and
notable hemorrhage appear to be important causes of
death in these individuals. Activated local megakaryo-
cytes in the lung, platelet aggregation, fibrin deposition,
and clot formation are involved with the mentioned
process [30]. Besides, the abundance of viral RNA in
neutrophils within the alveoli and the existence of some
degenerated neutrophils indicate the viral infection in
these cells [31]. Megakaryocyte response and platelet
production have also been reported in H1N1 influenza
infections [32]. Multifocal hepatic necrosis, mild
lymphocytic infiltration, sinusoidal dilation, and steatosis
are pathologic changes observed in the liver of COVID-
19 patients with moderate to severe illness [33]. Mild
myocardial hypertrophy changes and focal fibrosis are
tissue changes seen in the heart biopsies of death
COVID-19 patients [29]. Therefore, the researchers be-
lieve that effective therapy for COVID-19 should not be
limited only to the viral pathogen as a target, but also
the microangiopathic and thrombotic effects of the virus,
and body immune response to viral infection must be
considered in the disease management [34, 35].
The human angiotensin-converting enzyme 2 (ACE2),
known as the major receptor for the viral S protein pro-
vides the entry point for 2019-nCoV to capture and in-
fect a wide range of human cells. DC-SIGN (CD209),
CD147, and L-SIGN (CD209L) are also other entry re-
ceptors for 2019-nCoV. Thus, drugs that interfere with
the interactions of the spike protein/ACE2, CD147, DC-
SIGN or L-SIGN or with their gene expression may in-
hibit viral invasion.
ACE2 is found in many types of cells and tissues, in-
cluding the lungs, blood vessels, heart, liver, kidneys, and
gastrointestinal tract. It is also present in the epithelium
lining the lung, the nose, and mouth [36]. It is highly
abundant in type 2 pneumocytes, the important cells lo-
cated in alveoli, where oxygen exchanged with carbon
dioxide [37]. Regulating blood pressure and inflamma-
tion are the main functions of local ACE2 via the con-
version of angiotensin II (Ang II) to other molecules
that neutralize the effects of Ang II. It competes with
ACE (Angiotensin-converting enzyme) in hydrolyzing
inactive decapeptide Ang I. ACE2 hydrolyzes Ang I into
the nonapeptide Ang(1–9) and decreases the available
Ang I to be converted to AngII by ACE. It also hydro-
lyzes Ang II and Ang(1–9) into Ang(1–7). Unlike Ang
II, Ang(1–7) is a vasodilator with anti-inflammatory ef-
fects acting through Mas receptors [38]. Thus, ACE2 is a
negative regulator of local RAS in lung and other tissues.
Occupying the ACE2 receptor by SARS-CoV-2 prevents
it from performing its normal function, and breaking the
Ang I and Ang II peptides. Naturally, there is a high
concentration of ACE in the lung tissue. Thus, in ACE2
deficiency, ACE will be more active due to more avail-
able Ang I which is changed into Ang II. Increased local
Ang II levels damage blood vessel linings and cause in-
flammation and tissue injury. For this reason, it is
claimed that the renin-angiotensin- system has a serious
role in COVID-19 pathogenesis [39]. So it can be
claimed that the main destructive factor in the patients
with severe COVID-19 is abnormal and high activity of
local Ang II. Drugs that inhibit ACE or ACE inhibitors
(ACEI) such as ramipril, lisinopril, and enalapril may
prevent the injuries caused by Ang II via inhibiting its
production without blocking the actions of ACE2.
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In addition to ACE2, there are other enzymes capable
to hydrolyze Ang-I or Ang (1–9) to Ang (1–7) such as
Neprilysin, Prolylcarboxypeptidase, and Prolylendopepti-
dase. It appears that if the activity of these enzymes is
up-regulated in the lungs of people with COVID-19, the
effects of reduced ACE2 may be compensated. Among
the mentioned enzymes, higher expression levels of
Neprilysin have been detected in lung tissue, especially
in the membrane of pulmonary epithelial cells [40]. In
addition to the negative effect on Ang II production, it
cleaves and inactivates some other vasoactive peptides
such as substance P, and endothelin [41]. It degrades
and inactivates bradykinin. Bradykinin is identified as a
potent vasodilator and lowers blood pressure, but causes
contraction in the non-vascular smooth muscle of the
bronchi and intestines and may play a role in the pain
mechanism [42]. So, Neprilysin can be considered as a
potential target to control the severity of COVID-19
disease.
Both Prolylcarboxypeptidase and Prolylendopeptidase
are lysosomal and cytosolic peptidase, respectively, that
have been mainly expressed in white blood cells [43].
They have also been detected in lung, liver, and kidney
tissues. In addition to their role in the destruction or
maturation of a variety of peptides, both enzymes may
be considered as protective agents against AngII-
induced injuries due to the conversion of AngII to
Ang(1–7). Prolylcarboxypeptidase also named angioten-
sinase C, activates bradykinin, and hydrolyzes plasma
prekallikrein to active kallikrein [44]. However, some
studies have reported an inflammatory role for Prolylcar-
boxypeptidase in the lungs [45] and other tissues [46,
47].
Transmission of the 2019-nCoV
Rhinolophus affinis bat was introduced as the natural
host of 2019-nCoV due to 96.2% of whole-genome simi-
larity with the BatCoV-RaTG13 genome [48]. Evidence
indicates that the transmission of SARS-CoV and
MERS-CoV from an animal to a human requires an
intermediate host such as palm civets for SARS-CoV
and camels for MERS-CoV. Many researchers believe
that due to similarities between SARS-CoV and the
2019-nCoV, another animal as an intermediate host is
probably needed to transmit 2019-nCoV to humans. If
true, finding the intermediate 2019-nCoV host is vital to
prevent interspecies transmission. In this regard, pango-
lins have been suggested as an intermediate host for
2019-nCoV, however, this assumption has not yet been
proven [49, 50].
According to WHO, transmissions are classified as
scattered, clustered, and community-based. Scattered
cases refer to a small number of cases that are identified
locally. Local transmission shows the locations that have
been reported as a source of infection. A cluster of cases
refers to cases that are clustered in time, geographic lo-
cation, and/or by a common exposure. Community
transmission refers to the region experiencing higher
outbreaks of local transmission. It can be characterized
by a situation that the source of exposure cannot be
found or by a large number of cases that are not linkable
to transmission chains and are identified through sur-
veillance of a specific group of people [51, 52].
The routes of human-to-human transmission of
2019-nCoV among individuals include direct inhal-
ation of contaminated droplets released into the en-
vironment by sneezing or coughing, and contact
transmission via oral, nasal, and eye mucous [53]. Al-
though a 6-ft distance is emphasized to protect
against the spread of the disease, it is not enough.
Microbes in droplets < 5 μm in diameter can stay in
the air for a long time and can be transmitted to
others over distances of more than 1 m [54]. Dental
procedures are also a high-risk transmission route
due to face-to-face communication and the presence
of contamination with saliva, blood, and other body
fluids, as well as the use of sharp tools [55]. Trans-
mission may also happen through objects and per-
sonal items in the near environment around the
infected person. Therefore, COVID-19 can be trans-
mitted through direct contact with infected people or
indirectly, through the surfaces or objects contami-
nated by an infected person [56]. Positive COVID-19
patients extensively contaminate their bedrooms, toi-
lets and bathrooms; therefore, daily disinfection of
their living environment, high touch surfaces, bath-
tubs and toilet bowls is essential. Water places such
as swimming pools, rivers, lakes and ponds are also
places that may be exposed to contamination by posi-
tive COVID-19 people. There is no evidence that
2019-nCoV is spread through water in pools, rivers,
lakes [57]. To date, no reports of positive crowns
have been received from water play places [58]; how-
ever, it cannot be said that it is completely 100% safe.
Intestinal infection and the presence of 2019-nCoV in
feces have been reported, but there is not enough evi-
dence for fecal-oral transmission of 2019-nCoV. Song
et al. examined the presence of 2019-nCoV in testicular
biopsy and semen of COVID-19 patients and did not
find positive RT-PCR [59]. They stated that 2019-nCov
does not infect the testes and the virus may not be sexu-
ally transmitted by infected men. Some studies have
shown the presence of asymptomatic viral carriers with
normal laboratory and chest CT findings [60, 61]. The
mechanism by which asymptomatic carriers can obtain
and transmit 2019-nCoV requires further study. Thus,
an effective intervention is needed to prevent and con-
trol the spread of 2019-nCoV.
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Effect of COVID-19 on Other Organs
In addition to respiratory illnesses, which may be associ-
ated with pneumonia, sepsis, or lung failure, evidence
suggests that COVID-19 may affect other parts of the
body as well [62]. Figure 3 illustrates some common, un-
common, and severe symptoms in patients with
COVID-19.
According to several studies, 2019-nCoV infection,
similar to some viral infections, may be accompanied by
cardiac injury. A study of 400 patients hospitalized in
Wuhan, China, found that about one-fifth of patients
with COVID-19 developed heart disease, which in-
creased the mortality rate in patients [63]. Severe and
sudden inflammation of the heart muscle causes ar-
rhythmias and impairs the heart’s ability to efficiently
pump blood [64]. Therefore, patients with a history of
cardiovascular disease and with high blood pressure are
at higher risk of death than normal individuals. Oxygen
deficiency due to trauma in the lungs damages the lining
of the heart and blood vessels [65]. Besides, fatty plaques
in the arteries of the heart of people with or without
symptoms of cardiovascular disease may become un-
stable due to fever and inflammation, leading to vascular
obstruction and cardiovascular problems [66]. Other
possible disorders seen in hospitalized patients with
COVID-19 are abnormal blood clotting and venous
thromboembolism, which necessitate the administration
of anticoagulants or thromboprophylaxis for these pa-
tients [67]. The secretion of various types of inflamma-
tory cytokines in these conditions can exacerbate these
complications [2]. Thus, cytokine inhibitors may be ef-
fective in reducing the severity of the disease.
Some studies have reported that COVID-19 may dam-
age CNS. Some observed symptoms include losing the
senses of smell, taste or vision, and decreasing alertness
[68]. Also, seizures, stroke, and acute necrotizing
hemorrhagic encephalopathy have been reported in pa-
tients with severe COVID-19 infection [69]. Therapeutic
results have shown that neurological symptoms grad-
ually decrease in patients receiving viral encephalitis
treatment [70].
About half of patients with COVID-19 show evidence
of protein or blood in the urine, which indicates early
renal damage [71]. It has been reported that 15 to 30%
of hospitalized patients with COVID-19 in China and
New York need to receive renal treatments or dialysis
[72, 73]. However, the direct attack of the virus on the
kidneys is still being debated.
The presence of the virus in the fecal samples of some
patients with COVID-19 indicates that the virus can
reach the human gastrointestinal tract. About half of all
patients suffer from vomiting, diarrhea, and other
gastrointestinal disorders. Acute viral hepatitis has also
been found in some of these patients [74, 75]. After de-
veloping symptoms of fever and cough, physicians con-
nect gastrointestinal disorders with COVID-19.
Treatment of the COVID-19
Most viral infections target a series of “protective re-
sponses” in the host body, including apoptosis, stress re-
sponse, autophagy, and innate immunity. The strength
of the body’s protective response depends on genetics,
epigenetics, and or other factors, such as lifestyle [76].
The results of epidemiological and clinical studies show
that most of the infected individuals who are asymptom-
atic or show mild symptoms have good body capacity
for protective responses to activate the body’s antiviral
defense mechanisms including immune cell defense and
interferons induction. But, such supportive and immune
responses are weak in most elderly people or patients
Fig. 3 The systemic disorders caused by the COVID-19
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with immunodeficiency, lung problems such as fibrosis,
chronic obstruction and asthma, cardiovascular and
hypertension problems, diabetics, or obesity. Such in-
fected people may encounter more severe symptoms of
the disease, severe respiratory problems, and even death
[76–78]. Weak immune responses and inability to fight
the virus increase the viral load, leading to increased se-
cretion of inflammatory cytokine in the bronchoalveolar
lavage fluid and severe inflammatory/oxidative stress re-
sponse, followed by severe lung damage. Considering
acute respiratory distress syndrome, antiviral therapy,
antibiotics, corticosteroids, and anti-inflammatory drugs
are commonly used in treatment protocols [79].
Most drug designs against 2019-nCoV have been fo-
cused on immunomodulators (such as corticosteroids
and interferons), monoclonal antibody production, and
inhibitory agents against viral proteinase, helicase, and
polymerases [80]. However, to date, no specific antiviral
treatment or vaccine has been approved by the FDA for
COVID-19. Due to short replication times and high viral
yields, the replication of the positive-sense viral RNA
genome undergoes high error rates and homologous and
nonhomologous recombination. This genetic plasticity
makes it difficult to design an anti-COVID-19 drug and
vaccine [81, 82].
Clinical control of the disease is only based on symp-
toms via available therapeutic drugs, and in severe cases,
via supportive care including oxygen and mechanical
ventilation. The available therapeutic agents used for the
treatment of COVID-19 patients are antiviral agents in-
cluding Remdesivir, Chloroquine, Tocilizumab, Hydro-
xychloroquine, Umifenovir, Lopinavir, Oseltamivir, and
Favipiravir, and adjunctive agents such as zinc, vitamin
D, Azithromycin, Ascorbic acid, Nitric oxide, Corticoste-
roids, IL-6 antagonists. Because the viral load reaches its
peak around the time of symptom onset, the combin-
ation of multiple antiviral drugs, along with adjunctive
agents may quickly suppress the amount of virus in a pa-
tient’s body and may be effective in reducing the severity
of the disease and the duration of the viral infection
[83]. Vitamin D as an adjunctive agent can reduce the
risk of viral infections and prevent pneumonia and lung
damage through a variety of mechanisms, including re-
ducing the level of pro-inflammatory cytokines and in-
creasing the concentration of anti-inflammatory
cytokines [84]. Thus, Vit D may be effective in reducing
the severity of COVID-19 disease. Zinc is another ad-
junctive agent that is known for its antiviral, antibacter-
ial, and anti-inflammatory properties. It is involved in a
variety of mechanisms, including inhibition of NF-κB
signaling, regulation of T-cell, and restriction of cytokine
storms [85]. Speth et al. in their animal study reported
that zinc reduced the activity of recombinant human
ACE-2 in rat lungs [86].
The mentioned antiviral drugs are not specific to
2019-nCoV and may have limitations in use for treat-
ment. For example, Actemra (tocilizumab) is a monoclo-
nal antibody against the recombinant human IL-6
receptor from the IgG1τ subclass. At first, it was used to
treat rheumatoid arthritis and juvenile idiopathic arth-
ritis. Then, it was administered against cytokine storms
in coronavirus and influenza infections that are charac-
terized by high levels of IL-6 and other cytokines.
Actemra successfully could diminish the cytokine storm
associated with viral infections. Tian et al. in their re-
search proposed that due to high similarity among
receptor-binding domains in 2019-nCoV and SARS-
CoV, SARS-CoV-specific human monoclonal antibody,
CR3022, might also interact with 2019-nCoV spike pro-
tein and might be used as vaccines against COVID-19
disease, but CR3022 failed to bind 2019-nCoV spike pro-
tein. Thus, more research is needed to develop novel
monoclonal antibodies that can be specifically linked to
2019-nCoV RBD [87]. Other examples are Chloroquine
and Hydroxychloroquine, that have been used as anti-
malaria for more than 70 years and also as anti-
amoebiosis and anti-human immunodeficiency virus. In-
vitro and small clinical studies have shown that both
drugs could be effective against SARS-CoV infection and
prevent from the virus spread [88], but several clinical
studies have reported that administration of chloroquine
and hydroxychloroquine is associated with an increased
risk of heart problems in COVID-19 patients, including
cardiac arrhythmias and cardiac arrest [89].
In addition to chemical drugs, traditional herbal medi-
cines and convalescent plasma have also been suggested
to treat COVID-19. WHO believes that traditional, com-
plementary, and alternative medicine has many benefits.
Some countries including Iran, China, India, Korea, and
parts of Africa have a long history of traditional medicine
and have suggested medicinal guidelines for treating
COVID-19. For example, the Chinese have reported that
than 85% of COVID-19 patients in China had received
Traditional Chinese Medicine treatments. Due to the
similarity among SARS-CoV and 2019-nCoV in the
pathogenesis via using receptor ACE2 for host cell entry,
the same herbal medicines traditionally used for SARS-
CoV were also used for 2019-nCoV in China and Korea.
Some of the commonly used herbal medicine in China in-
clude Astragalus Membranaceus, Saposhnikoviae Divari-
cata, Glycyrrhiza Uralensis, Lonicerae Japonicae Flos,
Rhizoma, Atractylodis Macrocephalae, Atractylodis Rhi-
zoma, and Fructus forsythia. Some herbal products such
as Re Du Ning and Shen Fu have immunosuppressive ef-
fects via a decrease in the level of IL-1β, IL-6, IL-8, IL-10,
TNF-α, and other cytokines. The herbal formula of Qingfei
Paidu can regulate the immune-related pathway and re-
duce inflammation in lung and spleen of patients.
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Ayurveda, Siddha, Unani, and Homeopathy (referred
to as AYUSH) are Indian medicinal systems that use
natural drugs of plant, animal, and mineral origin for
treatment. At present pandemic, AYUSH has recom-
mended that the Homeopathy and Ayurveda as
immune-boosters have sufficient potential to prevent
and treat COVID-19. Considering the success of AYUSH
systems in managing several epidemics and restoring
health, AYUSH system recommends some herbs includ-
ing Chyavanprash, Herbal tea, and Turmeric milk as im-
mune boosters and has suggested some herbal
formulations for treating COVID-19 [90, 91].
In Iran, an herbal formula called Imam Kazem has
been reported by Islamic medicine, which is said to be
effective in treating colds and influenza. This herbal for-
mula was used for COVID-19 patients and they claimed
that it could prevent the disease from getting worse and
reduce the symptoms of the disease. The composition of
this herbal formula in summer is Terminalia chebula,
Foeniculum vulgare, and red sugar, and in winter it con-
sists of Terminalia chebula, Pistacia lentiscus and red
sugar (Red sugar means sugarcane sugar that has not
been processed industrially). Despite the positive reports
of this herbal formula in the treatment of lung diseases
in our country, no experimental or clinical reports were
found to refer. Rosewater as other herbal products is fla-
vored water made by steeping rose petals in water. In
addition to oral consumption, it has antimicrobial prop-
erties and can be sprayed on surfaces and space as a dis-
infectant solution [92].
Other examples of herbal medicine used in COVID-19
treatment include: Ginseng (Panax ginseng) regulates the
activity of immune cells including T cells, and B cells,
macrophages, dendritic cells, natural killer cells [93];
Ginger (Zingiber officinale) has anti-apoptotic, anti-
inflammatory, anti-tumor activities, anti-tumourigenic,
anti-hyperglycaemic, antioxidant, and analgesic proper-
ties [94]; garlic (Allium sativum) product is a strong im-
mune stimulator [95]; Echinacea extract (Echinacea
purpurea (L.) Moench) with antimicrobial and antioxi-
dant activities is used to improve the immune system
and to treat pulmonary symptoms caused by bacterial
infections [96].
Despite such treatments, there are few reports of im-
proved patients with negative COVID-19 test, that after
a while, their COVID-19 test has been positive again.
The hospital reports have confirmed, it is possible that
improved patients with negative COVID-19 tests be-
come positive again for 2019-nCoV RNA, although a
small portion of discharged COVID-19 has shown recur-
rent recurrences. There are reports of improved people
that showed second recurrences with positive PCR tests
after discharge from the hospital or during quarantine,
and were hospitalized again. These people were mostly
asymptomatic, but their blood IgM and IgG were still
positive [97–99]. Due to the possibility of recurrence of
the infection, all discharged patients should be quaran-
tined for at least 14 days and tested regularly for 2019-
nCoV RNA. During quarantine, they should avoid con-
tact with others because they may still be a virus carrier
and spread the infection to others.
Conclusions
2019-nCoV exists in the respiratory, fecal, and blood
samples of COVID-19 patients. However, the main route
of transmission is through inhalation of respiratory
droplets or contact with contaminated fomites due to
the persistence of the virus on surfaces. Although many
treatments have been proposed, there are currently no
specific options for treating COVID-19 or preventing
2019-nCoV infection. Like influenza, the prevalence of
COVID-19 is expected to decrease as the weather warms
up in the summer and the 2019-nCoV infection is pre-
dicted to start again with the gradual cooling of the air
in the fall. Unfortunately, it is not yet possible to say that
improved people from COVID-19 are resistant or sus-
ceptible to the second infection. Due to the high rate of
mortality and economic damage to various communities
to date, a significant attempt should be made to produce
successful drugs and vaccines against 2019-nCoV infec-
tion. However, in the absence of vaccines and antivirals,
the most important way to control the disease among
the populations is regular hand washing, the use of dis-
infectants, and the prevention of contact with the face
and mouth after interacting with the infected
environment.
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